Equity finance for ITM



ITM Isotope Technologies Munich SE has raised €188 million from a group of investors to prepare for the commercial launch of its lead radiopharmaceutical product and increase its manufacturing capacity for radioisotopes. The equity financing was led by Temasek Holdings Ltd, a Singapore-based investment group, and supported by four other entities including the Qatar Investment Authority. ITM has a pipeline of candidate radiopharmaceuticals and diagnostics for cancer as well as manufacturing agreements to supply medical radioisotopes to others, including Novartis.